P3 Health Partners (PIII) Q4 2024 earnings summary

Executive summary

• Revenue grew 18% year-over-year to $1.5 billion for 2024, with at-risk membership up 14% to 123,800.

• Focused on near-term profitability with programmatic initiatives targeting over $130 million in Adjusted EBITDA improvement, on schedule for 2025.

• Management reaffirmed 2025 guidance for all metrics except total members, which is slightly raised.

• Macro environment in Medicare is improving, with benefit design changes and payer bids signaling a more favorable outlook for 2026.

• Enhanced senior leadership with key hires to support operational execution and compliance.

Financial highlights

• Q4 2024 revenue was $370.7 million, up 7% year-over-year; full-year revenue reached $1.5 billion, up 18%.

• Membership increased 13% from Q4 2023 to Q4 2024; at-risk membership reached 123,800, up 14% year-over-year.

• Medical margin for 2024 was $85.5 million, down 37% from $135.1 million in 2023.

• Adjusted EBITDA loss for 2024 was $167.2 million, up from $85.5 million in 2023.

• Net loss for 2024 was $310.4 million, compared to $186.4 million in the prior year.

Outlook and guidance

• 2025 revenue guidance reaffirmed at $1.35–$1.5 billion; Adjusted EBITDA guidance at negative $35 million to $5 million positive.

• Medical Margin guidance for 2025 is $174–$210 million, with PMPM Medical Margin of $133–$147.

• Total membership expectation for 2025 increased to 109,000–119,000, driven by ACO growth.

• Expect to achieve profitability in 2025, with early trends supporting confidence in targets.

• Management cautions actual results may differ materially due to various risk factors.